OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Other research analysts also recently issued research reports about the company. Alliance Global Partners started coverage on OpGen in a report on Friday, March 1st. They set a “buy” rating and a $2.30 price objective on the stock. HC Wainwright set a $6.00 price objective on OpGen and gave the stock a “buy” rating in a report on Wednesday, December 5th.
NASDAQ:OPGN opened at $1.05 on Tuesday. OpGen has a 52 week low of $0.76 and a 52 week high of $2.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.20 and a current ratio of 1.32. The company has a market cap of $9.51 million, a price-to-earnings ratio of -0.47 and a beta of 1.14.
OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Tuesday, February 26th. The medical research company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.09). OpGen had a negative return on equity of 232.38% and a negative net margin of 453.73%. On average, research analysts forecast that OpGen will post -0.93 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in OpGen stock. Bank of New York Mellon Corp bought a new stake in shares of OpGen Inc (NASDAQ:OPGN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned about 0.24% of OpGen as of its most recent filing with the SEC. Institutional investors own 5.47% of the company’s stock.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Featured Article: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.